Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer
Overview
Tumor vaccines may make the body build an immune response to kill tumor cells. This research study is evaluating a new type of tumor vaccine termed as "Neoantigen Tumor Vaccine". The purpose of this phase I/II trial study is to assess the safety and effectiveness of neoantigentumor vaccine in post radical operation patients with stage IIIA lung cancer.
Full Title of Study: “Phase I/II Trial of Tumor Vaccine in Post Radical Operation Patients With Lung Cancer”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: January 31, 2025
Detailed Description
Outline: After successful vaccine manufacturing, patients receive neoantigen tumor vaccine hypodermically (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years). Treatment continues in the absence of disease recurrence and metastasis or unacceptable toxicity. Patients are followed for 2 years or up to the absence of disease recurrence and metastasis. Projected accrual: A total of 30 patients will be accrued for this study.
Interventions
- Biological: Tumor Vaccine
- NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
Arms, Groups and Cohorts
- Experimental: Tumor Vaccine
- Injection of NeoAntigen Tumor Vaccine
Clinical Trial Outcome Measures
Primary Measures
- Disease-free Survival (DFS)
- Time Frame: Approximately 2 years
- The time that participants stay free of cancer after surgery following administration of tumor vaccine
- Adverse Events (AEs)
- Time Frame: 30 days from first study vaccine administration
- Number of participants experiencing clinical and laboratory adverse events
Participating in This Clinical Trial
Inclusion Criteria
- Age: 18 to 70 years, Male or Female – Histological or cytologically diagnosis of lung adenocarcinoma – After surgical treatment (lobectomy and systematic lymph node dissection) – Pathological stage IIIA (According to the IASLC Lung Cancer Staging (eight Edition)) – Postoperative standard treatment (platinum-based double-drug adjuvant treatment with or without chemotherapy) or no adjuvant treatment – Have potential dynamic tumor biomarkers – Able and willing to give witnessed, written informed consent form prior to receiving any study related procedure, agree to participate in long-term follow-up for up to 3 years Exclusion Criteria:
- Age < 18 or< 70 years – Lung squamous cell carcinoma, small cell lung cancer, large cell lung cancer – Without surgical treatment – Pathological stage I、II、IIIB、IIIC or IV (According to the IASLC Lung Cancer Staging (eight Edition)) – Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study vaccine – Drug or alcohol abusers – Pregnant or breast-feeding patients – History of immunodeficiency disease or autoimmune disease – Patients with chronic disease which is undergoing immune reagents or hormone therapy – Concurrent other medical condition that would prevent the patient from undergoing protocol-based therapy – Lack of availability of a patient for immunological and clinical follow-up
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Yongchang Zhang
- Collaborator
- Shanghai Houchao Biotechnology Co., Ltd
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Yongchang Zhang, MD, pHD, Director of Thoracic Surgery Department II – Hunan Province Tumor Hospital
- Overall Official(s)
- Wenxiang Wang, MD, PhD, Principal Investigator, Hunan Provincal Tumor Hospital
- Overall Contact(s)
- Nong Yang, MD, +86 731 89762323, yangnong0217@163.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.